JAK2 and myelofibrosis: Discovery of JAK2V617F mutation and current progress in the molecule targeted treatment technologies lead to the development of JAK2 inhibitors which seem toyield promising results in selected groups of patients with myelofibrosis and created a certain enthusiasm.